221 related articles for article (PubMed ID: 26897272)
1. The Beneficial Effect of Beta-Blockers in Patients With Cirrhosis, Portal Hypertension and Ascites.
Aday AW; Mayo MJ; Elliott A; Rockey DC
Am J Med Sci; 2016 Feb; 351(2):169-76. PubMed ID: 26897272
[TBL] [Abstract][Full Text] [Related]
2. Beta-adrenergic blockade in cirrhosis - harmful or helpful?
Møller S; Danielsen KV; Nabilou P; Kimer N; Bendtsen F
Expert Rev Gastroenterol Hepatol; 2023; 17(6):519-529. PubMed ID: 37202907
[TBL] [Abstract][Full Text] [Related]
3. Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature.
Kimer N; Feineis M; Møller S; Bendtsen F
Scand J Gastroenterol; 2015 Feb; 50(2):129-37. PubMed ID: 25113796
[TBL] [Abstract][Full Text] [Related]
4. Prevention of Variceal Bleeding and Rebleeding by Nonselective Beta-Blockers: A Tailored Approach.
Jachs M; Reiberger T
Clin Liver Dis; 2021 May; 25(2):311-326. PubMed ID: 33838852
[TBL] [Abstract][Full Text] [Related]
5. Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers.
Hernández-Gea V; Aracil C; Colomo A; Garupera I; Poca M; Torras X; Miñana J; Guarner C; Villanueva C
Am J Gastroenterol; 2012 Mar; 107(3):418-27. PubMed ID: 22334252
[TBL] [Abstract][Full Text] [Related]
6. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis.
Mandorfer M; Bota S; Schwabl P; Bucsics T; Pfisterer N; Kruzik M; Hagmann M; Blacky A; Ferlitsch A; Sieghart W; Trauner M; Peck-Radosavljevic M; Reiberger T
Gastroenterology; 2014 Jun; 146(7):1680-90.e1. PubMed ID: 24631577
[TBL] [Abstract][Full Text] [Related]
7. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis.
Groszmann RJ; Garcia-Tsao G; Bosch J; Grace ND; Burroughs AK; Planas R; Escorsell A; Garcia-Pagan JC; Patch D; Matloff DS; Gao H; Makuch R;
N Engl J Med; 2005 Nov; 353(21):2254-61. PubMed ID: 16306522
[TBL] [Abstract][Full Text] [Related]
8. [The effect of propranolol on portal hypertension].
Kovacević N; Tomić D; Perisić-Savić M; Grbić R
Srp Arh Celok Lek; 1992 Jun; 120 Suppl 4():62-4. PubMed ID: 18193814
[TBL] [Abstract][Full Text] [Related]
9. Editorial: Beta-blockers and the prevention of decompensation in cirrhosis: worth the trouble.
Northup PG; Henry ZH
Am J Gastroenterol; 2012 Mar; 107(3):428-30. PubMed ID: 22388023
[TBL] [Abstract][Full Text] [Related]
10. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites.
Sersté T; Melot C; Francoz C; Durand F; Rautou PE; Valla D; Moreau R; Lebrec D
Hepatology; 2010 Sep; 52(3):1017-22. PubMed ID: 20583214
[TBL] [Abstract][Full Text] [Related]
11. NONSELECTIVE BETA-BLOCKERS IN PATIENTS WITH CIRRHOSIS: "THE THERAPEUTIC WINDOW".
Dimache M; Gîrleanu I; Carpov E; Trifan A; Stanciu C
Rev Med Chir Soc Med Nat Iasi; 2016; 120(1):23-8. PubMed ID: 27125068
[TBL] [Abstract][Full Text] [Related]
12. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.
Villanueva C; Aracil C; Colomo A; Hernández-Gea V; López-Balaguer JM; Alvarez-Urturi C; Torras X; Balanzó J; Guarner C
Gastroenterology; 2009 Jul; 137(1):119-28. PubMed ID: 19344721
[TBL] [Abstract][Full Text] [Related]
13. Preventing the development of varices in cirrhosis.
Garcia-Tsao G
J Clin Gastroenterol; 2007; 41 Suppl 3():S300-4. PubMed ID: 17975480
[TBL] [Abstract][Full Text] [Related]
14. Beta-blockers for prophylaxis of bleeding from esophageal varices in cirrhotic portal hypertension. Review of the literature.
Zoller WG; Gross M
Eur J Med Res; 1996 Jun; 1(9):407-16. PubMed ID: 9353240
[TBL] [Abstract][Full Text] [Related]
15. Is this really the end of beta-blockers in patients with cirrhosis and refractory ascites?
Thevenot T; Cervoni JP; Monnet E; Sheppard F; Martino VD
Hepatology; 2011 Feb; 53(2):715-6. PubMed ID: 20814893
[No Abstract] [Full Text] [Related]
16. Assessing the safety of beta-blocker therapy in cirrhosis patients with ascites: A meta-analysis.
Wong RJ; Robinson A; Ginzberg D; Gomes C; Liu B; Bhuket T
Liver Int; 2019 Jun; 39(6):1080-1088. PubMed ID: 30614656
[TBL] [Abstract][Full Text] [Related]
17. Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients.
Bossen L; Krag A; Vilstrup H; Watson H; Jepsen P
Hepatology; 2016 Jun; 63(6):1968-76. PubMed ID: 26599983
[TBL] [Abstract][Full Text] [Related]
18. Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites.
Sinha R; Lockman KA; Mallawaarachchi N; Robertson M; Plevris JN; Hayes PC
J Hepatol; 2017 Jul; 67(1):40-46. PubMed ID: 28213164
[TBL] [Abstract][Full Text] [Related]
19. Beta-blockers in patients with advanced liver disease: Has the dust settled?
Moctezuma-Velazquez C; Kalainy S; Abraldes JG
Liver Transpl; 2017 Aug; 23(8):1058-1069. PubMed ID: 28590564
[TBL] [Abstract][Full Text] [Related]
20. The changing role of beta-blocker therapy in patients with cirrhosis.
Ge PS; Runyon BA
J Hepatol; 2014 Mar; 60(3):643-53. PubMed ID: 24076364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
